Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be...
Leadership
Mark A. Goldsmith M.D., Ph.D.
CEO, President & Chairman
Jack Anders
Chief Financial Officer
Margaret A. Horn J.D.
Chief Operating Officer
Jeffrey Cislini J.D.
Senior VP, General Counsel & Corporate Secretary
Stephen M. Kelsey FRC Path., FRCP, M.D.
Senior Advisor
Martin D. Burke M.D., Ph.D.Founder
Co-Founder & Chairman of Scientific Advisory Board
Michael A. Fischbach Ph.D.Founder
Academic Co-Founder & Member of Scientific Advisory Board
Kevan M. Shokat Ph.D.Founder
Academic Co-Founder & Member of Scientific Advisory Board
